Rhumbline Advisers Rubius Therapeutics, Inc. Transaction History

Rhumbline Advisers

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.79 - $5.98 $37,056 - $280,503	-46,907 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$4.25 - $10.4 $4,734 - $11,585	-1,114 Reduced 2.32%	46,907 $258,000
Q4 2021 Feb 10, 2022	SELL	$9.68 - $17.74 $103,208 - $189,143	-10,662 Reduced 18.17%	48,021 $465,000
Q3 2021 Nov 12, 2021	BUY	$17.6 - $25.91 $29,075 - $42,803	1,652 Added 2.9%	58,683 $1.05 Million
Q2 2021 Aug 05, 2021	SELL	$22.26 - $28.43 $218,370 - $278,898	-9,810 Reduced 14.68%	57,031 $1.39 Million
Q1 2021 May 06, 2021	BUY	$8.02 - $32.01 $60,831 - $242,795	7,585 Added 12.8%	66,841 $1.77 Million
Q4 2020 Feb 10, 2021	BUY	$4.23 - $8.73 $34,994 - $72,223	8,273 Added 16.23%	59,256 $450,000
Q3 2020 Nov 12, 2020	SELL	$4.65 - $6.25 $34,247 - $46,031	-7,365 Reduced 12.62%	50,983 $255,000
Q2 2020 Aug 13, 2020	BUY	$4.01 - $6.88 $51,700 - $88,703	12,893 Added 28.36%	58,348 $349,000
Q1 2020 May 06, 2020	BUY	$3.74 - $9.84 $347 - $915	93 Added 0.21%	45,455 $202,000
Q4 2019 Feb 05, 2020	BUY	$7.23 - $14.12 $2,197 - $4,292	304 Added 0.67%	45,362 $431,000
Q3 2019 Oct 23, 2019	SELL	$7.85 - $15.75 $1,687 - $3,386	-215 Reduced 0.47%	45,058 $354,000
Q2 2019 Aug 14, 2019	BUY	$13.5 - $19.94 $43,308 - $63,967	3,208 Added 7.63%	45,273 $712,000
Q1 2019 May 01, 2019	BUY	$13.27 - $18.51 $341,516 - $476,373	25,736 Added 157.61%	42,065 $761,000
Q4 2018 Jan 31, 2019	BUY	$13.83 - $22.97 $106,643 - $177,121	7,711 Added 89.48%	16,329 $263,000
Q3 2018 Nov 07, 2018	BUY	$20.06 - $26.94 $172,877 - $232,168	8,618 New	8,618 $207,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.